News Highlights
6.23.2008
Replidyne Terminates Faropenem Agreements
5.7.2008
Replidyne Announces First Quarter 2008 Earnings Results
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products.
Replidyne's lead product, faropenem medoxomil (faropenem), is a novel oral community antibiotic, which we believe would be appropriate for use as a first-line antibiotic for certain respiratory and skin infections in adult and pediatric patients. Faropenem is in late stage clinical development in adult patients with acute bacterial sinusitis (ABS), acute exacerbation of chronic bronchitis (AECB), and community-acquired pneumonia (CAP). Faropenem has completed Phase II clinical trials for pediatric patients with acute otitis media (AOM).
Replidyne’s investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile-associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.